

# PROVIDER Update



CONTRACTUAL | NOVEMBER 21, 2025 | UPDATE 25-1223 | 3 PAGES

## Prior Authorization Updates Now in Effect – More Changes Coming in Early 2026

### Review new medication additions and removals, reclassifications and CMS code changes

The following updates to prior authorization (PA) requirements affect providers serving the Los Angeles County Department of Health Services (LA-DHS) members. These changes apply to outpatient pharmaceuticals (submitted under the medical benefit) and other select services.

**Note:** A correction to HCPCS code J3240 (Thyrogen®), effective December 1, 2025, is included at the end of this communication.

#### What's changing and when

- **New medications requiring PA** – effective immediately and February 1, 2026
- **Medication category reclassification** – effective immediately (no change to PA status)
- **Obsolete medication removed** – effective immediately
- **New Centers for Medicare & Medicaid Services (CMS) CPT/HCPCS codes with PA implications** – effective October 1, 2025

#### Accessing PA requirements

Access the *Medi-Cal Los Angeles County Department of Human Services (LA-DHS) Participating Provider Groups PA List* at <https://bit.ly/HN-Prior-Auth>.

#### Need help? Contact us

If you have questions regarding the information contained in this update, contact the Health Net Provider Services as listed in the right-hand column.

#### THIS UPDATE APPLIES TO:

- Physicians
- Participating Physician Groups
- Hospitals/Clinics
- Ancillary Providers
- Community Supports (CS) Providers
- Enhanced Care Management (ECM) Providers
- Behavioral Health Providers

#### LINES OF BUSINESS:

- Medi-Cal
  - Los Angeles

#### PROVIDER SERVICES

provider\_services@healthnet.com

**Medi-Cal (including CS and ECM providers)**

– 800-675-6110

**Behavioral Health providers –**

844-966-0298

#### PROVIDER PORTAL

provider.healthnetcalifornia.com

\*Health Net of California, Inc. and Health Net Community Solutions, Inc. are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at [provider.communications@healthnet.com](mailto:provider.communications@healthnet.com) indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

---

## Effective immediately

### Additions: New outpatient pharmaceuticals requiring PA

- Vabrinty™
  - Added to GnRH agonist examples
  - HCPCS code J9217 (existing PA requirement)
- Lutrate Depot
  - Added to GnRH agonist examples
  - HCPCS code J1954 (existing PA requirement)
- Bıldıyos® and Bilprevda®
  - Added to Denosumab agents
  - U.S. Food and Drug Administration (FDA)-approved September 2025
- Dawnzera™
  - Added to Hereditary Angioedema (HAE) agents as non-preferred
  - FDA-approved August 2025
- Keytruda Qlex™
  - Added to PD-1/PD-L1 inhibitors
  - FDA-approved September 2025
- Papzimeos™
  - Added to Gene therapy examples
  - FDA-approved August 2025

### Addition: Testosterone therapy

- HCPCS code J3145

### Changes: Medication category reclassifications (no change to PA requirements)

- Eylea®, Eylea HD, Enzeevu™, Pavblu™
  - Moved to Aflibercept agents category
- Velcade®, Boruzu™
  - Moved to Bortezomib agents category

### Removal:

- Obsolete medication – Fusilev®
  - No longer commercially available
  - PA requirements unchanged
  - Levoleucovorin (Khapzory™) continues to require PA

## Effective February 1, 2026

### Addition: New medication requiring PA

- Jobevne™
  - Added to Bevacizumab agents as non-preferred
  - FDA-approved April 2025

## New CMS CPT/HCPCS codes with PA requirements, effective October 1, 2025

The procedures, services (including durable medical equipment) and outpatient pharmaceuticals listed in the table below require PA per new CPT and HCPCS codes issued by the CMS.

CPT Copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

Service category	Drug name	Codes	PA rule
<b>Custom orthotics</b>	N/A	L1007	PA required
<b>Durable medical equipment</b>	N/A	E0658 – E0659	PA required if > \$1500 billed
<b>Genetic testing</b>	N/A	0575U – 0576U, 0578U, 0582U – 0583U, 0585U – 0586U, 0592U, 0597U	PA required
<b>Outpatient pharmaceuticals</b>	IMAAVY™	C9305	PA required
	Emrelis™	C9306	
	Grafapex™	J0614	
	Nulibry®	J1809	
	Ryoncil®	J3402	
	Datroway®	J9011	
• <b>Gene therapy</b>	Encelto™	J3403	
• <b>Self-Injectable</b>	Alhemo®	J7173	
	Qfitlia™	J7174	
• <b>Omalizumab agents</b>	Omlyclo®	Q5154	
• <b>Aflibercept agents</b>	Yesafili™	Q5155	
• <b>Tocilizumab agents</b>	Avtozma®	Q5156	
• <b>Denosumab agents</b>	Stoboclo®/ Osenvelt®	Q5157	
	Bomynta®/ Conexence®	Q5158	
	Ospomyv™ and Xbryk™	Q5159	
<b>Proprietary laboratory analysis</b>	N/A	0577U, 0579U, 0591U, 0596U, 0598U – 0599U	PA required
<b>Prosthetics</b>	N/A	L5657, L6034 – L6036, L6038 – L6039	PA required

### Correction: HCPCS code update for Thyrogen®

Effective December 1, 2025, **HCPCS code J3240 (Thyrogen®)** will require prior authorization under Outpatient pharmaceuticals.

This code was previously listed incorrectly as J3420 in provider update 25-999, *Streamlining Prior Authorization: Simplifying Processes for Better Efficiency*, distributed on September 24, 2025.